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Abstract: Smooth muscle cell (SMC) migration contributes to
vascular remodeling. Nitric oxide (NO) produced via endothelial
NO synthase (eNOS) inhibits SMC migration. This study analyzes
signal transduction mechanisms of SMC migration targeted by NO.
SMCs were cultured from human saphenous veins, and cell migration
was studied using Boyden chambers. PDGF-BB (0.1 to 10 ng/ml)
stimulated SMC migration in a concentration-dependent manner,
which was inhibited by adenoviral-mediated overexpression of eNOS
and by the NO donor diethylentriamine NONOate (DETANO, 10-5 to
10-3 mol/L). NO release was enhanced in eNOS-transduced SMCs,
and L-NAME blunted the effect of eNOS overexpression on
migration. PDGF-BB (10 ng/ml) activated Rho A, which was
inhibited by the overexpression of eNOS by DETANO and by
8 bromo-cGMP. The inhibitory effect of DETANO on Rho A activity
was prevented by the cGMP-dependant kinase inhibitor. Furthermore,
inhibition of Rho A by C3 exoenzyme and inhibition of ROCK by
Y-27632 diminished cell migration stimulated by PDGF-BB. Finally,
in the cells overexpressing constitutively active ROCKmutant (CAT),
DETANO failed to prevent PDGF-BB–induced SMC migration. In
conclusion, NO inhibits human SMC migration via blockade of the
Rho A pathway.
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INTRODUCTION
Migration of smooth muscle cells (SMCs) is an essential
event in vascular remodeling and thus in the development of
vascular diseases such as atherosclerosis, restenosis, and
bypass vein graft disease.1–3 Many growth factors such as
PDGF, bFGF, and thrombin are potent mediators of cell
migration.4–6 Although an interaction of SMCs with extracel-
lular matrix has been shown to play an important role in SMC
migration,7 intracellular signal transduction pathways acti-
vated by migratory stimuli are mostly undeﬁned.
Stimulation of SMCs with growth factors or chemo-
attractants is associated with activation of an array of signal
transduction pathways including p44/p42mapk, p70S6K, and
the small GTP binding protein Rho GTPases activated
either through tyrosine kinase receptors or G-protein coupled
receptors.8–10 These molecules transmit extracellular growth
signals into the cell nucleus, thereby activating transcription
factors and regulating downstream gene expression and
cellular responses. The Rho GTPases form a novel subgroup
of the Ras superfamily of 20- to 30-kDa GTP-binding proteins.
Rho GTPases function as molecular switches, cycling between
an inactive GDP-bound state and an active GTP-bound state
and are involved in transcriptional regulation and cell
proliferation/migration control. Rho A is one member of
a distinct group of Rho-like proteins.10
NO produced from L-arginine via endothelial nitric
oxide synthase (eNOS) is a potent vasodilator, platelet
inhibitor, and reduces SMC proliferation and migration.11,12
NO can affect proteins involved in cell cycle regulation and in
turn induce cell cycle arrest.13–15 However, it is still unclear
through which signal transduction pathways NO regulates
SMC migration. Therefore, the aim of this study focused
on the intracellular signal transduction pathways of cell migra-
tion targeted by NO in human SMCs, with particular emphasis
on Rho A pathway.
METHODS
Materials
All materials for cell culture were purchased from
GibcoBRL (Basel, Switzerland). Clostridium Botulinum
C3 exoenzyme,16 DietylentriamineNONOate (DETANO),17
and KT582318 were from Calbiochem (Luzern, Switzerland).
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Rabbit polyclonal antibodies against phospho-p44/p42mapk
and phospho-p70S6K were from New England BioLabs
(Allschwil, Switzerland); Rho A (SC-119) was purchased
from Santa Cruz Biotechnology Inc. (Basel, Switzerland).
Mouse monoclonal antibody against human eNOS (N30020)
was from Transduction Laboratories (Basel, Switzerland). The
ROCK inhibitor Y-2763216 was kindly provided by Welﬁde
Corporation, Osaka, Japan.
Recombinant Adenovirus
An adenoviral vector for expression of human placental
alkaline phosphatase (AdhpAP) and a control virus without
transgene (AdDE1) were derived from Ad5 sub360 and pre-
pared as described.19 A similar virus for expression of eNOS
(adeNOS) was provided by Dr. Stephan Janssens, Leuven,
Belgium. Expression of adeNOS was driven by a CMV pro-
moter, while the AdDE1 had no insert (for details see refer-
ence 15). Adenoviral vectors for expression of constitutively
active ROCK mutant (CAT) and LacZ were generated using
the CMV promoter in the pEF-BOS-myc-RB/PH (TT) vector
as described elsewhere.20 The titer of puriﬁed viruses was
determined by plaque assay on 293 cells.
Culture of Human SMCs
SMCs were cultured from saphenous veins (SVs)
obtained from patients undergoing coronary bypass surgery
using an explant technique.21 The patients gave informed
consent in accordance with the Declaration of Helsinki. The
cells were cultured in DMEM containing 20% FCS
supplemented with 20 mmol/l L-glutamine and 10 mmol/l
HEPES buffer solution, 100 U/ml penicillin, and 100 mg/ml
streptomycin in a humidiﬁed atmosphere (95% air/5% CO2) at
37C. Culture medium was replaced every 3 days. Cells were
passaged by cell dissociation solution. Experiments were
performed on passage 4–7. SMCs were characterized by their
typical morphological pattern and by indirect immunoﬂuo-
rescence staining by using speciﬁc mouse monoclonal
antibodies against human SMC a-actin.21
Gene Transfer
SMCs were incubated with a viral titer of 1000 pfu/cell
for 1 hour in DMEM containing 2% FCS at 37C in
a humidiﬁed atmosphere and then kept in DMEM with 10%
FCS for 24 hours. The transfer efﬁciency was analyzed using
AdhpAP and determined 24 hours after infection by ﬁxing the
cells in 1.25% glutaraldehyde (Sigma, Buchs, Switzerland)
and staining with NBT/BCIP (GIBCO) as described.19 The
eNOS expression was analyzed by Western blot. The cells for
further experiments were then kept in serum-free medium for
24 to 48 hours. SMCs infected with AdDE1 or LacZ and
uninfected cells served as negative controls for all experiments.
Migration Assay
Vascular smooth muscle cells were grown to conﬂuence
in DMEM medium supplemented with 10% fetal bovine
serum. Cells were detached from the plate by trypsinization,
and migration efﬁciency was tested using a 48-well Boyden
chamber (Neuroprobe Inc., Cabin John, MD) in the presence
of 10 ng/ml PDGF as a chemotactic agent. A total of 25,000
cells per group were used for migration experiments. For
adenoviral transduction, cells were seeded at 40% conﬂuence
and left in the incubator for 24 hours. Cells were transfected as
described and treated with or without the eNOS inhibitor
L-NAME, the Rho A inhibitor exoenzyme-C3 or the ROCK
inhibitor Y-27632 at indicated concentrations for 30 minutes.
Cells were allowed to migrate for 5 hours at 37C/5%CO2.
Nonmigrated cells were removed from the upper side with
a cell scraper, and migrated cells from the bottom side were
ﬁxed in ice-cold methanol, stained with Diffquick solution
I and II (Medion Diagnostics, switzerland), and counted on
4 different ﬁelds as described.22
Activation of p44/42mapk and p70s6k
Quiescent human saphenous vein SMC rested in serum-
free medium for 48 hours were stimulated with PDGF-BB
(10 ng/ml). After stimulation, the cells were washed with ice-
cold PBS and harvested with cold extraction buffer (120 mmol/l
sodium chloride, 50 mmol/l Tris, 20 mmol/l sodium ﬂuoride,
1 mmol/l benzamidine, 1 mmol/l DTT, 1 mmol/l EDTA,
6 mmol/l EGTA, 15 mmol/l sodium pyrophosphate, 0.8 mg/ml
leupeptin, 30 mmol/l p-nitrophenylphosphate, 0.1 mmol/l
PMSF, and 1% Nonidet P40). Twenty micrograms of
cell extracts were boiled at 95C for 10 minutes in Laemmli
SDS-PAGE sample buffer (50 mmol/l Tris-Cl, 100 mmol/l
DTT, 2% SDS, 0.1% bromophenol blue, and 10% glycerol)
and subjected to 10% SDS-PAGE gels for electrophoresis.
Proteins were then transferred onto Immobilon-P ﬁlter papers
(Millipore AG) with a semidry transfer unit. Equal loading was
controlled by staining with Ponceau S. Membranes were then
blocked by 5% skim milk in PBS-Tween buffer (0.1% Tween
20) for 1 hour and incubated with the primary antibodies (the
anti-phospho-p44/42mapk antibody, 1:1000; anti-phospho-p70S6K
antibody, 1:1000). The immunoreactive bands were detected
by use of an enhanced chemiluminescence (ECL) system
(Amersham).
Rho A Membrane Translocation
Conﬂuent and quiescent SMCs were stimulated with
PDGF-BB (10 ng/ml). The cells were then washed twice with
cold PBS and then harvested in PBS buffer containing
2 mmol/l EDTA, 2 mmol/l phenylmethylsulfonyl ﬂuoride, and
1 mmol/l leupeptin. The cells were then disrupted by brief
sonication on ice. The samples were then centrifuged at 5003 g
for 10 minutes at 4oC to remove the nucleus. The membrane
and cytosolic portions were then separated by centrifugation at
100,000 3 g for 1 hour at 4oC (Airfuge; Beckman Instru-
ments, Inc., Nyon, Switzerland). The cell membranes were
washed once with the above-mentioned buffer and then
resuspended in buffer containing 100 mmol/l Tris-HCl,
300 mmol/l NaCl, 1% Triton X-100, and 0.1% SDS containing
2 mmol/l EDTA, 2 mmol/l PMSF, and 1 mmol/l leupeptin.
Equal amounts of protein (10 mg) were loaded into 12% SDS-
PAGE gels and applied to electrophoresis. Western blot was
then performed with the antibody against Rho A (1:1000).
Rho A Activity
Rho A activity was determined by pull-down assay. The
cell lysates were incubated with agarose-conjugated Rhotekin











for 45 minutes. The agarose beads were collected and run in
12% SDS-PAGE gels. Western blot was performed using the
antibody against Rho A.
Expression of eNOS
eNOS expression was analyzed by Western blot. The
SMCs were kept in DMEM containing 10% FCS for 24 hours
after transduction. Cells were then harvested with cold
extraction buffer, and 20 mg of protein was loaded on to
8% SDS-PAGE as described above. The eNOS antibody
(1:600) was used as the primary antibody.
Nitric Oxide Release
SMCs were grown in DMEM medium supplemented
with 10% fetal bovine serum. A total of 70,000 cells were
seeded in a 12-well plate at 40% conﬂuence and incubated for
24 hours before transfection. After transfection, 10% DMEM
was replaced, and cells were incubated for additional 24 hours.
Cells were prepared according to the manufacturer’s instruc-
tions in the presence of DETC (Noxygen, Germany) and
FeSO4. Nitric oxide levels were measured with e-scan
(BRUKER). Data were calculated and represented in nano-
moles/minute/number of cells.
Statistical Analyses
Data are presented as mean 6 SEM. Rho A trans-
location was expressed as percent increase above control. In all
experiments, n equals the number of patients from which cells
were obtained; in the migration assay, every experiment was
done in triplicates. Statistical analyses were performed with
unpaired t test between 2 groups and analysis of variance among
more than 3 groups. P , 0.05 was considered signiﬁcant.
RESULTS
Overexpression of eNOS Inhibits
SMC Migration
In cultured SMCs, PDGF-BB (0.1, 1, and 10 ng/ml)
stimulated cell migration in a concentration-dependent manner
(8 6 2, 28 6 3, and 76 6 4 cells/ﬁeld of vision compared to
control 6 6 2; P , 0.05 for 1 and 10 ng/ml). Cell migration
stimulated by PDGF (10 ng/ml) was concentration depen-
dently inhibited by the NO donor, DETANO (Figure 1A).
Overexpression of eNOS in SMCs was achieved with an
adenoviral vector. A viral titer of 1000 pfu/cell was used and
resulted in 99% transfected SMCs (data not shown). Expres-
sion of eNOS in SMCs was further evidenced by Western blot
(Figure 1B insert). eNOS overexpression signiﬁcantly reduced
PDGF-induced cell migration (Figure 1B). Although the
control adenovirus (AdDE1) tended to have some inhibitory
effects, this did not reach statistical signiﬁcance. Exposure of
SMCs to AdDE1 or AdeNOS did not exert any cytotoxic
effects as determined by LDH release (n = 3; P = not signiﬁ-
cant; data not shown). Adenoviral overexpression of eNOS
enhanced NO release from SMCs (n = 4; P , 0.05; data not
shown). The inhibitory effect of adeNOS on SMC migration
was blunted by L-NAME (Figure 1C).
FIGURE 1. NO inhibits human SMC migration. (A) Treatment
of the cells with the NO donor DETANO (10-5 to 10-3 mol/l)
inhibited the migratory activity of SMCs in response to
PDGF-BB (10 ng/ml, 4 hours) in a concentration-dependent
manner. (B) Migration to PDGF-BB (10 ng/ml) was also
inhibited by adenoviral eNOS (AdeNOS) transfer. eNOS gene
expression in human SMCs was evidenced by Western blot
(insert, n = 4). (C) L-NAME (3 3 10-4 mol/L) blunted the effect
of AdeNOS on SMC migration. *P , 0.05 versus PDGF alone.
**P, 0.05 versus empty vector. †P, 0.001 versus PDGF alone.











NO Inhibits SMC Migration Via Inhibition of
Rho A
The cell migration stimulated by PDGF-BB was
associated with activation of various signal transduction
pathways such as Rho A, p44/42mapk, and p70s6k. PDGF-BB
(10 ng/ml) time-dependently stimulated Rho A membrane
accumulation, which is the crucial step for activation of the
GTPase (Figure 2A). Activation of Rho A reached the
maximum at 30 to 60 minutes (Figure 2A). We could not
detect signiﬁcant changes of Rho A in cytosolic fraction,
possibly due to a large amount of Rho A in cytoplasm. The
Rho A membrane accumulation stimulated by PDGF-BB
(10 ng/ml, 30 minutes) was prevented by DETANO (10-4
mol/l) (Figure 2B) and by eNOS overexpression (Figure 2C),
although the vector alone also had some nonsigniﬁcant effect.
Rho A activity was also evaluated with pull-down assay.
Similar to the membrane translocation assay, PDGF-BB
(10 ng/ml) also increased Rho A activity in SMCs, with the
maximal effect at 30 minutes after the stimulation (Figure 3A).
Total Rho A amount was not affected by PDGF until
60 minutes. The increase in Rho A activity stimulated by
PDGF-BB (10 ng/ml, 30 minutes) was prevented by DETANO
(10-4 mol/l) and 8-bromo cGMP (10-4 mol/l) (Figure 3B). The
inhibition of cGMP-dependent kinase by KT5823 (10-7 mol/l)
blocked the suppressive effect of DETANO on Rho A activity
(Figure 3B).
In addition to Rho A, PDGF-BB also activated
p44/42mapk and p70s6k in cultured SMCs. PDGF-BB (10 ng/ml,
10 minutes) phosphorylated p44/42mapk and p70s6k as demon-
strated by Western blots using speciﬁc antibodies against
phospho-p44/42mapk and phospho-p70s6k. The NO donor
DETANO (10-4 mol/l) alone stimulated, rather than inhibited,
p44/42mapk, but it did not inﬂuence the activation of p44/42mapk
or p70s6k in response to PDGF-BB (10 ng/ml, data not shown).
Inhibition of Rho A and ROCK Inhibits
SMC Migration
The migratory activity of human SMCs stimulated by
PDGF-BB (10 ng/ml) was reduced by the Rho A inhibitor
50 mg/ml C3 exoenzyme (Figure 4A) as well as by the
downstream kinase ROCK inhibitor Y-27632 (Figure 4B).
Overexpression of Constitutively Active ROCK
Mutant Blocks the Effect of NO
To get direct evidence that the inhibitory effect of NO on
SMC migration is mediated by inhibition of Rho/ROCK
pathway, we investigated the effect of overexpression of con-
stitutively active ROCK mutant (CAT). DETANO (10-4 mol/l)
again prevented PDGF-BB–induced SMC migration in
the cells infected with control adenoviruses for expression
of LacZ. On the other hand, DETANO failed to prevent
PDGF-BB-induced SMCmigration in the cells overexpressing
constitutively active ROCK mutant (CAT) (Figure 5).
FIGURE 2. Effects of NO on Rho Amembrane translocation. (A)
Membrane translocation of Rho A was stimulated by PDGF-BB
(10 ng/ml) in a time-dependent manner, which reached the
maximum at 30 minutes. (B and C) Rho A translocation in
response to PDGF-BB (10 ng/ml, 30 minutes) was reduced by
the NO donor DETANO (10-4 mol/l) or by adenoviral eNOS
gene transfer. *P , 0.05 versus PDGF alone. **P , 0.05 versus
empty vector.
FIGURE 3. Effects of NO on Rho A activity. (A) Activity of Rho A
determined by pull-down assay was stimulated by PDGF-BB
(10 ng/ml) in a time-dependent manner, which reached the
maximum at 30 minutes. (B) Rho A activity in response to
PDGF-BB (10 ng/ml, 30 minutes) was reduced by the NO
donor DETANO (10-4 mol/l) and 8-bromo cGMP (10-4 mol/l).
cGMP-dependent kinase inhibitor KT5823 blocked the inhib-
itory effect of DETANO on Rho A activity. Similar results were












In human SMCs, NO provided by the overexpression of
eNOS gene with a recombinant adenovirus vector or added
directly through an NO donor inhibits the cell migration in
response to PDGF via inhibition of the Rho A pathway.
SMC migration essentially contributes to intimal thick-
ening and vascular remodeling in atherosclerosis, restenosis,
and venous bypass graft disease.1–3 Almost all peptide growth
factors, such as PDGF, are also important activators of SMC
migration.1–3 In this study, we selected PDGF as a migratory
signal and obtained concentration-dependent stimulation of
human SMC migration. We and the other group reported that
NO inhibits migration of rat and human arterial SMCs.11,12 We
used DETANO as a pharmacological source of NO because
this molecule exhibits very slow and prolonged release
kinetics of the free radical, which is most suitable for cell
culture experiments.21 Overexpression of eNOS provides
a novel concept for the inhibition of SMC proliferation and
migration in vascular diseases such as restenosis and venous
bypass graft disease.23–25 Using an adenoviral vector, we
successfully transferred eNOS into human vascular SMCs as
demonstrated by Western blot. Previous studies demonstrated
a very high transfer rate (99%) under these experimental
conditions,19 which was also achieved in the current experi-
ments. As in previous studies, the control virus did exert some
nonspeciﬁc effects; however, the pronounced effects of the
eNOS adenovirus can be blocked by L-NAME,15 demonstrat-
ing that NO indeed is involved.
Expression of eNOS in saphenous vein SMCs was
associated with important biological effects. Indeed, eNOS
gene transfer markedly reduced PDGF-induced migration of
SMCs. Although the empty virus tended to have some effects
as well, this did not reach statistical signiﬁcance. PDGF-
induced migration of SMCs was associated with activation of
a series of intracellular signal transduction pathways such as
p44/42mapk, p70s6k, and Rho A. In particular, PDGF increased
the activity of Rho A as well as its membrane accumulation.
High local levels of NO provided either pharmacologically
with DETANO or via adenovirus-mediated eNOS gene
transfer reduced the activity and the translocation of Rho A.
In addition to Rho A, PDGF-BB also activated p44/42mapk
or p70s6k in cultured SMCs. However, NO did not inhibit
the activation of either p44/42mapk or p70s6k in response to
PDGF-BB, suggesting that the effects of NO on the RhoA
pathway are very speciﬁc. Evidence for the involvement of the
Rho A pathway as a mediator of the antimigratory effects of
NO was further strengthened by experiments with the speciﬁc
inhibitors and the constitutively active ROCK mutant. Indeed,
consistent with the report by the other group,26 the migratory
activity of PDGF in SMCs was reduced in the presence of the
FIGURE 4. Inhibition of Rho A and ROCK suppresses SMC
migration. PDGF-BB (10 ng/ml) increased the number of
migrated cells within 4 hours, which was inhibited (A) by a
speciﬁc Rho A inhibitor C3 exoenzyme (50 mg/ml) or (B) by a
downstream kinase ROCK inhibitor Y-27632 in a concentration-
dependent manner. *P , 0.05 versus PDGF alone.
FIGURE 5. Overexpression of constitutively active ROCK
mutant blocks the inhibitory effect of NO. In the cells
overexpressing active ROCK mutant (CAT), the inhibitory
effect of DETANO (10-4 mol/l) on SMC migration induced by












Rho A inhibitor C3 exozyme27 as well as the ROCK inhitor
Y-2763228; conversely, the effects of NO were prevented by the
overexpression of constitutively active ROCK mutant (CAT).
In addition, we investigated the mechanistic insights into
how NO blocks Rho A activity. In general, the effects of NO
on cellular functions are mediated by cGMP-dependent and
independent mechanisms. We hypothesized that cGMP path-
way might mediate the inhibitory action of NO on Rho A
activity. Indeed, the cGMP analogue, 8-bromo cGMP pre-
vented the increase in Rho A activity stimulated by PDGF and
the cGMP-kinase inhibitor, KT5823 blocked the suppressive
effect of NO on Rho A activity, suggesting that cGMP/cGMP-
dependent kinase pathway plays an important role in this
action. It was recently reported that cGMP-dependent kinase
directly phosphorylates and inactivates Rho A.29 The same
mechanism may be involved in the inhibition of Rho A activity
by NO in human SMCs.
This study demonstrated that the Rho A pathway is
a target of NO to exert its antimigratory effects in human
vascular SMCs. This therefore provides a new therapeutic
approach for the treatment of human vascular disease
associated with increased migration of SMCs, such as
restenosis and venous bypass graft disease.
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